07:30 AM EDT, 07/17/2025 (MT Newswires) -- Rocket Pharmaceuticals ( RCKT ) said Thursday that the US Food and Drug Administration has granted regenerative medicine advanced therapy, or RMAT, designation to RP-A601, the company's experimental gene therapy for PKP2-arrhythmogenic cardiomyopathy, a heart condition.

The designation was based on safety and efficacy data from a phase 1 trial. The designation offers key benefits like closer FDA guidance, faster development, potential accelerated approval and priority review of the therapy's future biologics license application, the company said.

Shares of Rocket Pharmaceuticals ( RCKT ) rose more than 6% in recent premarket Thursday activity.

Price: 3.05, Change: +0.19, Percent Change: +6.64